Results 61 to 70 of about 164 (114)

Protein-oligopeptide fragmentomics

, 2008
8
openaire   +2 more sources

The SChISM study: Circulating cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

BackgroundCirculating cell-free DNA (cfDNA) offers a promising noninvasive way to predict resistance to immune-checkpoint inhibitors (ICI), for which robust biomarkers are still lacking.MethodsThe SChISM (Size CfDNA Immunotherapy Signature Monitoring ...
Boutonnet, Audrey, Fina, Frederic, Della-Negra, Lucie, Nguyen Phuong, Linh, Tomasini, Pascale, Greillier, Laurent, Zakrasjek, Romain, Garcia, Jean-Charles, Salas, Sébastien, Ginot, Frédéric, Deville, Jean-Laurent, Benzekry, Sébastien   +11 more
core   +4 more sources

Integrating tumor kinetics and circulating cell-free DNA markers through mechanistic modeling for early prediction of immunotherapy response

International audienceMany cancer patients undergoing immune-checkpoint inhibition (ICI) experience early progression(EP), defined as progression at the first imaging evaluation.
Fina, Frederic, Nguyen Phuong, Linh, Greillier, Laurent, Gaudy-Marqueste, Caroline, Garcia, Jean-Charles, Salas, Sébastien, Deville, Jean-Laurent, Benzekry, Sébastien   +7 more
core   +1 more source

Seminal plasma cfDNA fragmentomics landscape delineates male infertility subtypes

Clinical Epigenetics
Abstract Background While cell-free DNA (cfDNA) fragmentomics has transformed liquid biopsy applications in prenatal screening and oncology, its potential in male reproductive health remains uncharted. Methods Through integrated whole-genome sequencing and jagged end sequencing (Jag-Seq) coupled with non-CpG methylation analysis, we ...
Wu, Xiaoyu, Meng, Fan, Zhang, Huiping, Li, Zeqing, Zhao, Kai   +4 more
openaire   +2 more sources

Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors

International audienceIntroduction: Despite a significant proportion (20 to 40%)[1] of advanced cancer patients having long-term response to treatment with immune checkpoint inhibitors (ICI), many of them do not respond at all and experience early ...
Boutonnet, Audrey, Fina, Frederic, Nguyen Phuong, Linh, Greillier, Laurent, Gaudy-Marqueste, Caroline, Salas, Sébastien, Ginot, Frédéric, Deville, Jean-Laurent, Benzekry, Sébastien   +8 more
core   +2 more sources

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

International audienceAbstract Locally advanced esophageal carcinoma remains of poor prognosis correlated with tumor stage. Albeit liquid biopsy approach offers promising results to monitor high‐risk patients in various solid tumors, the lack of specific
Le Sourd, Samuel, Jouve, Ariane Darut, Gibert, Sophie, Taillez, Alexandre, Modesto, Anouchka, Vendrely, Véronique, Seva, Catherine, Delmas, Caroline, Ronchin, Philippe, Leignel, Delphine Argo, Guimbaud, Rosine, Moyal, Elizabeth, Riou, Olivier, Delord, Jean Pierre, Cordelier, Pierre, Pezzella, Veronica, Paumier, Amaury, Martin-Babau, Jérôme, Tougeron, David, Leroy, Thomas, Quéro, Laurent, Hanoun, Naima   +21 more
core   +1 more source

Cancer‐Like Fragmentomic Characteristics of Somatic Variants in Cell‐Free DNA

Advanced Science
ABSTRACT Cell‐free DNA (cfDNA) in plasma consists of short DNA fragments resulting from a non‐random fragmentation process, with distinct fragmentomic characteristics that are related with their cellular origins. Here, we report that somatic variant signatures in cfDNA markedly differ between non‐cancerous controls and cancer patients,
Zhenyu Zhang, Yunyun An, Mengqi Yang, Yuqi Pan, Xiaoyi Liu, Fanglei Gong, Huizhen Lin, Bianbian Tang, Yunxia Bai, Xin Zhao, Yu Zhao, Changzheng Du, Kun Sun   +12 more
openaire   +2 more sources

DeepFRAG: a method for cancer detection based on DNA fragmentomics and deep learning

Bioinformatics Advances
Abstract Motivation Cancer screening using liquid biopsy technology has become standard in modern clinical and preventive oncology. This method analyzes cell-free DNA (cfDNA) circulating in a patient’s bloodstream.
Andrey Koch, Eldar Giladi
openaire   +3 more sources

pyfraglib : An integrated cfDNA fragmentomics platform

Abstract Summary Cell-free DNA (cfDNA) fragmentomics is the analysis of a diverse set of cfDNA fragment features, e.g. fragment length profiles, windowed protection scores, and end motifs. As such it requires software tooling for fragment extraction, statistical feature modeling,
Daniel Schuette, Laura K. Godfrey, Jessica Schneider, Sven Borchmann, Jan-Michel Heger, Roland F. Schwarz   +5 more
openaire   +1 more source

Mechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy

BackgroundPlasma cell-free DNA (cfDNA) shows promise as predictive cancer biomarker, but mechanisms governing cfDNA production/fragmentation/elimination dynamics, and their relationships with tumor burden and disease progression, remain poorly understood.
Boutonnet, Audrey, Salas, Sebastien, Nguyen Phuong, Linh, Tomasini, Pascale, Greillier, Laurent, Garcia, Jean-Charles, Ginot, Frédéric, Deville, Jean-Laurent, Fina, Frédéric, Benzekry, Sébastien   +9 more
core   +3 more sources